Live Breaking News & Updates on National centre for adverse drug reaction monitoring

Stay informed with the latest breaking news from National centre for adverse drug reaction monitoring on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in National centre for adverse drug reaction monitoring and stay connected to the pulse of your community

No deaths can be directly linked to Covid-19 vaccines, Parliament told | Malaysia

KUALA LUMPUR, Nov 23 ― There are no death cases that can be directly linked to the Covid-19 vaccines administered during the implementation period of the National Covid-19 Vaccination Programme (PICK) from February 24 until November 20. Deputy Health Minister ll, Datuk Aaron Ago Dagang said this...

Kuala-lumpur , Malaysia , Dewan-rakyat , Instagram , Vaccine-special-pharmacovigilance-committee , National-pharmaceutical-regulatory-agency , Aaron , Health-ministry , National-centre-for-adverse-drug-reaction-monitoring , Pfizer , Astrazeneca , National-covid

Q & A: What you need to know about the Pfizer-BioNTech Covid-19 vaccine

Q: What types of Covid-19 vaccines have been registered?
A: NPRA’s Drug Control Authority has granted Comirnaty conditional registration on Jan 8. Each dose of Comirnaty contains 30µg of nucleoside modified mRNA strand formulated as an RNA-lipid nanoparticle that encodes the viral spike (S) protein of the SARS-CoV-2, the virus responsible for Covid-19.
Q: What are the conditions for the vaccine’s registration?
A: Since the application was based on rolling submission of the latest data, the Product Registration Holder (PRH) will need to ensure all outstanding documents are submitted and deemed satisfactory by NPRA according to the timeline given. Apart from that, the PRH is required to monitor the safety profile of the vaccine and inform NPRA as soon as possible of any untoward incidents. The PRH is also required to conduct all activities planned under the Risk Management Plan and submit a monthly safety summary report to NPRA.

Malaysia , Drug-control-authority , Pfizer , National-centre-for-adverse-drug-reaction-monitoring , National-pharmaceutical-regulatory-agency , Health-ministry , Control-authority , Product-registration-holder , Risk-management-plan , National-centre , Adverse-drug-reaction-monitoring